In conclusion, our results revealed that the pharmacological advantage of the combination of MTX plus HDACIs in lymphoma cells stemmed from their synergistic effects on the increased synthesis of long-chain MTX-PGs and decreased expression of DHFR by HDACIs, which is a main target of MTX. Here, DHFR is linked to lymphoma.